{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:27:59Z","timestamp":1793863679088,"version":"4.6.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    \u03b2-amyloid (A\u03b2) pathology is not always coupled with Alzheimer\u2019s disease (AD) relevant cognitive decline. We assessed the accuracy of tau PET to identify A\u03b2(+) individuals who show prospective disease progression. 396 cognitively unimpaired and impaired individuals with baseline A\u03b2 and tau PET and a follow-up of \u2265 2 years were selected from the Alzheimer\u2019s Disease Neuroimaging Initiative dataset. The participants were dichotomously grouped based on either clinical conversion (i.e., change of diagnosis) or cognitive deterioration (fast (FDs) vs. slow decliners (SDs)) using data-driven clustering of the individual annual rates of cognitive decline. To assess cognitive decline in individuals with isolated A\u03b2(+) or absence of both A\u03b2 and tau (T) pathologies, we investigated the prevalence of non-AD comorbidities and FDG PET hypometabolism patterns suggestive of AD. Baseline tau PET uptake was higher in A\u03b2(+)FDs than in A\u03b2(-)FD\/SDs and A\u03b2(+)SDs, independently of baseline cognitive status. Baseline tau PET uptake identified MCI A\u03b2(+) Converters and A\u03b2(+)FDs with an area under the curve of 0.85 and 0.87 (composite temporal region of interest) respectively, and was linearly related to the annual rate of cognitive decline in A\u03b2(+) individuals. The T(+) individuals constituted largely a subgroup of those being A\u03b2(+) and those clustered as FDs. The most common biomarker profiles in FDs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200970) were A\u03b2(+)T(+) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200934, 49%) and A\u03b2(+)T(-) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919, 27%). Baseline A\u03b2 load was higher in A\u03b2(+)T(+)FDs (M\u2009=\u200983.03\u2009\u00b1\u200931.42CL) than in A\u03b2(+)T(-)FDs (M\u2009=\u200963.67\u2009\u00b1\u200926.75CL) (\n                    <jats:italic>p<\/jats:italic>\n                    -value\u2009=\u20090.038). Depression diagnosis was more prevalent in A\u03b2(+)T(-)FDs compared to A\u03b2(+)T(+)FDs (47% vs. 15%,\n                    <jats:italic>p<\/jats:italic>\n                    -value\u2009=\u20090.021), as were FDG PET hypometabolism pattern not suggestive of AD (86% vs. 50%,\n                    <jats:italic>p<\/jats:italic>\n                    -value\u2009=\u20090.039). Our findings suggest that high tau PET uptake is coupled with both A\u03b2 pathology and accelerated cognitive decline. In cases of isolated A\u03b2(+), cognitive decline may be associated with changes within the AD spectrum in a multi-morbidity context, i.e., mixed AD.\n                  <\/jats:p>","DOI":"10.1038\/s41380-024-02672-9","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:32:04Z","timestamp":1724419924000},"page":"587-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer\u2019s disease compared to comorbid cases; proof of concept in the ADNI study"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7204-1330","authenticated-orcid":false,"given":"Konstantinos","family":"Ioannou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-8651","authenticated-orcid":false,"given":"Marco","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Tzortzakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Savitcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-5151","authenticated-orcid":false,"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5679-0297","authenticated-orcid":false,"given":"Konstantinos","family":"Chiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"2672_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/brain\/awq349","volume":"134","author":"A Kadir","year":"2011","unstructured":"Kadir A, Marutle A, Gonzalez D, Sch\u00f6ll M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer\u2019s disease. Brain. 2011;134:301\u201317.","journal-title":"Brain"},{"key":"2672_CR2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurology. 2018;75:1062\u201370.","journal-title":"JAMA Neurology"},{"key":"2672_CR3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"2672_CR4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with \u03b2-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74:905\u201313.","journal-title":"Ann Neurol"},{"key":"2672_CR5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study. Alzheimer\u2019s & Dementia. 2015;11:964\u201374.","journal-title":"Alzheimer\u2019s & Dementia."},{"key":"2672_CR6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","volume":"63","author":"ER Fantoni","year":"2018","unstructured":"Fantoni ER, Chalkidou A, O\u2019 Brien JT, Farrar G, Hammers A. A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease. 2018;63:783\u201396.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"2672_CR7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"2672_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","volume":"52","author":"K Chiotis","year":"2017","unstructured":"Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214\u201327.","journal-title":"Neurobiol Aging"},{"key":"2672_CR9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","volume":"75","author":"RO Roberts","year":"2018","unstructured":"Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology. 2018;75:970\u20139.","journal-title":"JAMA Neurology"},{"key":"2672_CR10","doi-asserted-by":"crossref","first-page":"e66877","DOI":"10.1371\/journal.pone.0066877","volume":"8","author":"S Hatashita","year":"2013","unstructured":"Hatashita S, Yamasaki H. Diagnosed Mild Cognitive Impairment Due to Alzheimer\u2019s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction. PLoS One. 2013;8:e66877.","journal-title":"PLoS One"},{"key":"2672_CR11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3233\/JAD-141965","volume":"47","author":"K Farid","year":"2015","unstructured":"Farid K, Carter SF, Rodriguez-Vieitez E, Almkvist O, Andersen P, Wall A, et al. Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. J Alzheimers Dis. 2015;47:661\u20137.","journal-title":"J Alzheimers Dis"},{"key":"2672_CR12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.25333","volume":"84","author":"D Bergeron","year":"2018","unstructured":"Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, et al. Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018;84:729\u201340.","journal-title":"Ann Neurol"},{"key":"2672_CR13","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1212\/WNL.0000000000207393","volume":"101","author":"P Diaz-Galvan","year":"2023","unstructured":"Diaz-Galvan P, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, et al. \u03b2-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies. Neurology. 2023;101:e178\u2013e188.","journal-title":"Neurology"},{"key":"2672_CR14","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748\u201363.","journal-title":"Brain"},{"key":"2672_CR15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:eaau5732.","journal-title":"Sci Transl Med"},{"key":"2672_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42:631\u20139.","journal-title":"Neurology"},{"key":"2672_CR17","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A, Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26:5888\u201398.","journal-title":"Mol Psychiatry"},{"key":"2672_CR18","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1038\/s41380-020-0815-4","volume":"26","author":"K Chiotis","year":"2021","unstructured":"Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, et al. 18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26:5875\u201387.","journal-title":"Mol Psychiatry"},{"key":"2672_CR19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"2672_CR20","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137.","journal-title":"Nat Med"},{"key":"2672_CR21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurology. 2019;76:915\u201324.","journal-title":"JAMA Neurology"},{"key":"2672_CR22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","volume":"22","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, et al. Amyloid-\u03b2 and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer\u2019s disease. Mol Psychiatry. 2017;22:306\u201311.","journal-title":"Mol Psychiatry"},{"key":"2672_CR23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaneurol.2016.2078","volume":"73","author":"L Wang","year":"2016","unstructured":"Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between \u03b2-Amyloid and Tauopathy. JAMA Neurol. 2016;73:1070\u20137.","journal-title":"JAMA Neurol"},{"key":"2672_CR24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"2672_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-210614","volume":"84","author":"E Colato","year":"2021","unstructured":"Colato E, Chiotis K, Ferreira D, Mazrina MS, Lemoine L, Mohanty R, et al. Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer\u2019s Disease. JAD. 2021;84:103\u201317.","journal-title":"JAD"},{"key":"2672_CR26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neurobiolaging.2017.09.002","volume":"60","author":"A Soldan","year":"2017","unstructured":"Soldan A, Pettigrew C, Cai Q, Wang J, Wang M-C, Moghekar A, et al. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer\u2019s disease. Neurobiol Aging. 2017;60:164\u201372.","journal-title":"Neurobiol Aging"},{"key":"2672_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-06624-y","volume":"7","author":"D Gamberger","year":"2017","unstructured":"Gamberger D, Lavra\u010d N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer\u2019s disease. Sci Rep. 2017;7:6763.","journal-title":"Sci Rep"},{"key":"2672_CR28","volume":"11","author":"SH Cho","year":"2021","unstructured":"Cho SH, Woo S, Kim C, Kim HJ, Jang H, Kim BC, et al. Disease progression modelling from preclinical Alzheimer\u2019s disease (AD) to AD dementia. Sci Rep. 2021;11:4168.","journal-title":"Sci Rep"},{"key":"2672_CR29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578\u201386.","journal-title":"Ann Neurol"},{"key":"2672_CR30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol. 2013;74:826\u201336.","journal-title":"Ann Neurol"},{"key":"2672_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimer\u2019s. Res Ther. 2021;13:99.","journal-title":"Res Ther"},{"key":"2672_CR32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14:1565\u201371.","journal-title":"Alzheimers Dement"},{"key":"2672_CR33","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2672_CR34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurology. 2020;77:829\u201339.","journal-title":"JAMA Neurology"},{"key":"2672_CR35","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143:3477\u201394.","journal-title":"Brain"},{"key":"2672_CR36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358.","journal-title":"Ann Neurol"},{"key":"2672_CR37","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","volume":"139","author":"AJ Schwarz","year":"2016","unstructured":"Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539\u201350.","journal-title":"Brain"},{"key":"2672_CR38","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018;320:1151\u201362.","journal-title":"JAMA"},{"key":"2672_CR39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-022-00986-w","volume":"14","author":"AJ Weigand","year":"2022","unstructured":"Weigand AJ, Maass A, Eglit GL, Bondi MW. What\u2019s the cut-point?: a systematic investigation of tau PET thresholding methods. Alzheimers Res Ther. 2022;14:49.","journal-title":"Alzheimers Res Ther"},{"key":"2672_CR40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clinimag.2022.06.005","volume":"89","author":"CM Wilson","year":"2022","unstructured":"Wilson CM, Selwyn RG, Elojeimy S. Comparison of PET\/CT SUV metrics across different clinical software platforms. Clin Imaging. 2022;89:104\u20138.","journal-title":"Clin Imaging"},{"key":"2672_CR41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961\u201370.","journal-title":"JAMA Neurol"},{"key":"2672_CR42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. J Alzheimers Dis. 2018;63:423\u201344.","journal-title":"J Alzheimers Dis"},{"key":"2672_CR43","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6:502\u201316.","journal-title":"Brain Imaging Behav"},{"key":"2672_CR44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jalz.2013.12.025","volume":"11","author":"KJ Bangen","year":"2015","unstructured":"Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:394\u2013403.e1.","journal-title":"Alzheimers Dement"},{"key":"2672_CR45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jagp.2013.01.043","volume":"21","author":"LB Zahodne","year":"2013","unstructured":"Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G, Alzheimer\u2019s Disease Neuroimaging Initiative. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? Am J Geriatr Psychiatry. 2013;21:1098\u2013106.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2672_CR46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2023.12.008","volume":"136","author":"JP Ferrari-Souza","year":"2024","unstructured":"Ferrari-Souza JP, Brum WS, Hauschild LA, Da Ros LU, Ferreira PCL, Bellaver B, et al. Vascular risk burden is a key player in the early progression of Alzheimer\u2019s disease. Neurobiol Aging. 2024;136:88\u201398.","journal-title":"Neurobiol Aging"},{"key":"2672_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00401706.1977.10489493","volume":"19","author":"RD Cook","year":"1977","unstructured":"Cook RD. Detection of Influential Observation in Linear Regression. Technometrics. 1977;19:15\u201318.","journal-title":"Technometrics"},{"key":"2672_CR48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/sim.1974","volume":"24","author":"E Demidenko","year":"2005","unstructured":"Demidenko E, Stukel TA. Influence analysis for linear mixed-effects models. Stat Med. 2005;24:893\u2013909.","journal-title":"Stat Med"},{"key":"2672_CR49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"2672_CR50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2672_CR51","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/brain\/awv236","volume":"138","author":"H Braak","year":"2015","unstructured":"Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer\u2019s disease. Brain. 2015;138:2814\u201333.","journal-title":"Brain"},{"key":"2672_CR52","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Murray ME, Knopman DS, Przybelski SA, Wiste HJ, et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain. 2018;141:1201\u201317.","journal-title":"Brain"},{"key":"2672_CR53","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.0000000000002480","volume":"86","author":"LR White","year":"2016","unstructured":"White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology. 2016;86:1000\u20138.","journal-title":"Neurology"},{"key":"2672_CR54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171\u201386.","journal-title":"Acta Neuropathol"},{"key":"2672_CR55","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1212\/WNL.0b013e31826c1b9d","volume":"79","author":"RY Lo","year":"2012","unstructured":"Lo RY, Jagust WJ, Alzheimer\u2019s Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012;79:1349\u201355.","journal-title":"Neurology"},{"key":"2672_CR56","doi-asserted-by":"crossref","first-page":"e031947","DOI":"10.1136\/bmjopen-2019-031947","volume":"9","author":"N Goukasian","year":"2019","unstructured":"Goukasian N, Hwang KS, Romero T, Grotts J, Do TM, Groh JR, et al. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. BMJ Open. 2019;9:e031947.","journal-title":"BMJ Open"},{"key":"2672_CR57","doi-asserted-by":"publisher","unstructured":"Landau SM, Lee J, Murphy A, Ward TJ, Harrison TM, Baker SL, et al. Individuals with Alzheimer\u2019s disease and low tau burden: Characteristics and implications. Alzheimers Dement. 2024. 19 January 2024. https:\/\/doi.org\/10.1002\/alz.13609.","DOI":"10.1002\/alz.13609"},{"key":"2672_CR58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.21706","volume":"66","author":"JA Schneider","year":"2009","unstructured":"Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200\u20138.","journal-title":"Ann Neurol"},{"key":"2672_CR59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6:82.","journal-title":"Alzheimers Res Ther"},{"key":"2672_CR60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neurobiolaging.2019.01.008","volume":"77","author":"AM Wennberg","year":"2019","unstructured":"Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Machulda MM, et al. The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging. 2019;77:26\u201336.","journal-title":"Neurobiol Aging"},{"key":"2672_CR61","doi-asserted-by":"crossref","first-page":"e2282","DOI":"10.1212\/WNL.0000000000200287","volume":"98","author":"KA Josephs","year":"2022","unstructured":"Josephs KA, Weigand SD, Whitwell JL. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. Neurology. 2022;98:e2282\u2013e2292.","journal-title":"Neurology"},{"key":"2672_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2018.3","volume":"4","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:1\u201316.","journal-title":"Nat Rev Dis Primers"},{"key":"2672_CR63","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:532\u20139.","journal-title":"Alzheimers Dement"},{"key":"2672_CR64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243:213\u201321.","journal-title":"Exp Biol Med"},{"key":"2672_CR65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307.","journal-title":"Front Public Health"},{"key":"2672_CR66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13195-023-01205-w","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Ye T, Zhou W, Zhang J. for the Alzheimer\u2019s Disease Neuroimaging Initiative. Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. Alzheimer\u2019s. Res Ther. 2023;15:57.","journal-title":"Res Ther"},{"key":"2672_CR67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000504341","volume":"48","author":"ML Phillips","year":"2019","unstructured":"Phillips ML, Stage EC Jr., Lane KA, Gao S, Risacher SL, Goukasian N, et al. Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer\u2019s Disease Subjects: Evidence for Disease Heterogeneity. Dement Geriatr Cogn Disord. 2019;48:131\u201342.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2672_CR68","volume":"7","author":"DM Rentz","year":"2021","unstructured":"Rentz DM, Wessels AM, Annapragada AV, Berger A-K, Edgar CJ, Gold M, et al. Building clinically relevant outcomes across the Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2021;7:e12181.","journal-title":"Alzheimers Dement"},{"key":"2672_CR69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WAD.0b013e3182351c04","volume":"26","author":"AK Zaleta","year":"2012","unstructured":"Zaleta AK, Carpenter BD, Porensky EK, Xiong C, Morris JC. Agreement about diagnosis among patients, companions, and professionals following a dementia evaluation. Alzheimer Dis Assoc Disord. 2012;26:232\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2672_CR70","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3233\/JAD-170527","volume":"62","author":"MA Sugarman","year":"2018","unstructured":"Sugarman MA, Alosco ML, Tripodis Y, Steinberg EG, Stern RA. Neuropsychiatric Symptoms and the Diagnostic Stability of Mild Cognitive Impairment. J Alzheimers Dis. 2018;62:1841\u201355.","journal-title":"J Alzheimers Dis"},{"key":"2672_CR71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jalz.2011.08.007","volume":"8","author":"JW Han","year":"2012","unstructured":"Han JW, Kim TH, Lee SB, Park JH, Lee JJ, Huh Y, et al. Predictive validity and diagnostic stability of mild cognitive impairment subtypes. Alzheimer\u2019s & Dementia. 2012;8:553\u20139.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2672_CR72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"2672_CR73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"2672_CR74","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neurobiolaging.2017.01.021","volume":"52","author":"M Boccardi","year":"2017","unstructured":"Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, et al. The biomarker-based diagnosis of Alzheimer\u2019s disease. 2-lessons from oncology. Neurobiol Aging. 2017;52:141\u201352.","journal-title":"Neurobiol Aging"},{"key":"2672_CR75","doi-asserted-by":"crossref","first-page":"e1142","DOI":"10.1212\/WNL.0000000000200817","volume":"99","author":"E Borland","year":"2022","unstructured":"Borland E, Edgar C, Stomrud E, Cullen N, Hansson O, Palmqvist S. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages. Neurology. 2022;99:e1142\u2013e1153.","journal-title":"Neurology"},{"key":"2672_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"2672_CR77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/jnnp.2009.204008","volume":"81","author":"SJ Cano","year":"2010","unstructured":"Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer\u2019s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81:1363\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2672_CR78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-150128","volume":"47","author":"EC Edmonds","year":"2015","unstructured":"Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW, Alzheimer\u2019s Disease Neuroimaging Initiative. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer\u2019s Disease. J Alzheimers Dis. 2015;47:231\u201342.","journal-title":"J Alzheimers Dis"},{"key":"2672_CR79","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","volume":"78","author":"DS Knopman","year":"2012","unstructured":"Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576\u201382.","journal-title":"Neurology"},{"key":"2672_CR80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-018-0459-7","volume":"11","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Chipi E, Salvadori N, D\u2019Andrea K, Eusebi P. Prevalence and risk of progression of preclinical Alzheimer\u2019s disease stages: a systematic review and meta-analysis. Alzheimers Res Ther. 2019;11:7.","journal-title":"Alzheimers Res Ther"},{"key":"2672_CR81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fdata.2020.00024","volume":"3","author":"LL Raket","year":"2020","unstructured":"Raket LL. Statistical Disease Progression Modeling in Alzheimer Disease. Front Big Data. 2020;3:24.","journal-title":"Front Big Data"},{"key":"2672_CR82","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1037\/a0029857","volume":"27","author":"RS Wilson","year":"2012","unstructured":"Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The Natural History of Cognitive Decline in Alzheimer\u2019s Disease. Psychol Aging. 2012;27:1008\u201317.","journal-title":"Psychol Aging"},{"key":"2672_CR83","first-page":"424","volume":"72","author":"KB Rajan","year":"2017","unstructured":"Rajan KB, Wilson RS, Barnes LL, Aggarwal NT, Weuve J, Evans DA. A Cognitive Turning Point in Development of Clinical Alzheimer\u2019s Disease Dementia and Mild Cognitive Impairment: A Biracial Population Study. J Gerontol A Biol Sci Med Sci. 2017;72:424\u201330.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2672_CR84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000339365","volume":"39","author":"L Yu","year":"2012","unstructured":"Yu L, Boyle P, Wilson RS, Segawa E, Leurgans S, De Jager PL, et al. A random change point model for cognitive decline in Alzheimer\u2019s disease and mild cognitive impairment. Neuroepidemiology. 2012;39:73\u201383.","journal-title":"Neuroepidemiology"},{"key":"2672_CR85","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"RL Joie","year":"2019","unstructured":"Joie RL, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multi-site study of the relationships between ante mortem [11C]PIB-PET Centiloid values and post mortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"2672_CR86","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2672_CR87","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2672_CR88","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","volume":"48","author":"S Ng","year":"2007","unstructured":"Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer\u2019s Disease. J Nucl Med. 2007;48:547\u201352.","journal-title":"J Nucl Med"},{"key":"2672_CR89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-021-00785-9","volume":"13","author":"F Levin","year":"2021","unstructured":"Levin F, Ferreira D, Lange C, Dyrba M, Westman E, Buchert R, et al. Data-driven FDG-PET subtypes of Alzheimer\u2019s disease-related neurodegeneration. Alzheimers Res Ther. 2021;13:49.","journal-title":"Alzheimers Res Ther"},{"key":"2672_CR90","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s13311-021-01027-4","volume":"18","author":"AJ Schwarz","year":"2021","unstructured":"Schwarz AJ. The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Neurotherapeutics. 2021;18:686\u2013708.","journal-title":"Neurotherapeutics"},{"key":"2672_CR91","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198005153022003","volume":"302","author":"SG Pauker","year":"1980","unstructured":"Pauker SG, Kassirer JP. The Threshold Approach to Clinical Decision Making. N Engl J Med. 1980;302:1109\u201317.","journal-title":"N Engl J Med"},{"key":"2672_CR92","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.943860","volume":"123","author":"MJ Pletcher","year":"2011","unstructured":"Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation. 2011;123:1116\u201324.","journal-title":"Circulation"},{"key":"2672_CR93","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112\u201334.","journal-title":"Mol Psychiatry"},{"key":"2672_CR94","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"M-L Malarte","year":"2023","unstructured":"Malarte M-L, Gillberg P-G, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2023;28:1272\u201383.","journal-title":"Mol Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02672-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T14:34:56Z","timestamp":1737383696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02672-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02672-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data used in preparation of this article were obtained from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) database (\n                      \n                      ). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and\/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consortia"}}]}}